Regulatory
Preparing Pharma Marketers for the Impact of Prop 24
The recently passed California Privacy Rights and Enforcement Act (CPRA or Prop 24) will ...
What You Need to Know About the Trump Administration’s Final Rule on Transparency in Coverage
In a continued push for increasing price transparency in healthcare, the Trump administration recently ...
Best Laid Plans: 3 Obstacles to Prepare for in Your State Licensing Strategy
As the pandemic creates unique working and regulatory situations from state to state, manufacturers ...
Compliant and Creative DTC Pharma Campaigns: What’s the Secret?
Diving headfirst into a direct-to-consumer (DTC) campaign can be an exciting new challenge, but ...
Leveraging Emergency Use Authorizations to Bring COVID-19 Products to Market
With the emergence of the COVID-19 crisis, the scientific and medical communities have been ...
Diminishing Risk for Risk-averse Regulators
The life sciences can simultaneously be thought of as one of the most risk-taking ...
What Are the Basics of Cannabis Law?
Although naturally produced cannabis has enjoyed legalization in certain states, it remains, on the ...
Public Health Crises and FDA Scrutiny
Every public health emergency or outbreak brings with it a corresponding urgent need for ...
3 Keys to Launch a Website Within Hours of FDA Approval
Launching a drug website the same day you receive FDA approval for a new ...
The FDA, Marketing Claims, and Digital Health Products
For both developers and marketers of digital health products, a thorough evaluation of each ...
MLR Comments: Friend or Foe?
When I tell people that I work in pharma marketing, I occasionally get a ...
The Impact Colorado’s New Prescription Drug Law Will Have on Marketers
The General Assembly of the State of Colorado recently enacted a statute aimed at ...
GDPR: Where We’ve Come, Where We are Going
Recently, I wrote about Google’s $57 million fine for violating the now one-year old ...
